Personal dosimetry of the staff during treatment of neuroendocrine tumours with a high dose of Indium-111 Octreotide

Quarterly Journal of Nuclear Medicine

Volumn 46, Issue 4, 2002, Pages 331-335

  Stokkel, M P M ^a   Boot, I N ^a   Smit, J W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Indium radioisotopes; Neuroendocrine tumours, therapy; Radiometry

Indexed keywords

PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR;

ARTICLE; AUGER ELECTRON SPECTROSCOPY; CALIBRATOR; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DOSE RESPONSE; DOSIMETER; DOSIMETRY; DRUG CLEARANCE; DRUG MEGADOSE; DRUG USE; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; MEDICAL SPECIALIST; MEDICAL STAFF; MONITOR; NEUROENDOCRINE TUMOR; OCCUPATIONAL EXPOSURE; PHARMACIST; RADIATION EXPOSURE; RADIATION HAZARD; SAFETY; TUMOR REGRESSION; WHOLE BODY SCINTISCANNING;

ALLIED HEALTH PERSONNEL; CARCINOMA, NEUROENDOCRINE; ENVIRONMENTAL EXPOSURE; HUMANS; NEOPLASM METASTASIS; OCCUPATIONAL EXPOSURE; OCTREOTIDE; RADIATION DOSAGE; RADIATION PROTECTION; RADIOMETRY; RADIOPHARMACEUTICALS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; WHOLE-BODY COUNTING;

EID: 0036892174     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Van Eijck CHJ, de Jong M, Breeman WAP, Slooter GD, Marquet RL, EP Krenning. Somatostatin receptor imaging and therapy of pancreatic endocrine tumours. Ann Oncol 1999;10:S177-81.
2. Krenning EP, Kooij PPM, Pauwels S, Breeman WAP, Postema PTE, de Herder WW et al. Somatostatin receptor: scintrigraphy and radionuclide therapy. Digestion 1996;57:57-61.
3. Reubi JC, Schar J-C, Waser B, Wenger S, Heppeler A, Schmitt JS et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphy and radiotherapeutic use. Eur J Nucl Med 2000;27:273-82.
4. McCarthy KE, Woltering EA, Anthony LB. In situ radiotherapy with In111-pentetreotide. Q J Nucl Med 2000;44:88-95.
5. De Jong M, Breeman WAP, Bernard HF, Kooij PPM, Slooter GD, van Eijck CHJ et al. Therapy of neuroendocrine tumors with radio-labeled somatostatin analogues. Q J Nucl Med 1999;43:356-66.
6. Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG et al. Bio-kinetics and dosimetry in patients administered with In-111-DOTA-Tyr-3-octreotide: implications for internal radiotherapy with Y-90-DOTATOC. Eur J Nucl Med 1999;26:877-86.
7. Caplin ME, Mielcarek W, Buscombe JR, Jones AL, Croasdale PL, Cooper MS, et al. Toxicity of high-activity In-111-Octreotide therapy in patients with disseminated neuroendocrine tumours. Nucl Med Commun 2000;21:97-102.
8. Bernard BF, Krenning EP, Breedman WAP, Rolleman EJ, Bakker WH, Visser TJ et al. D-lysine reduction of Indium-111 Octreotide and Yttrium-90 Octreotide renal uptake. J Nucl Med 1997;38:1929-33.
9. Van Dijk JWE. Quality assurance in individual monitoring: 10 years of performance monitoring of the TLD based TNO individual monitoring service. Rad Prot Dosim 1998;77:235-40.
10. Clarke EA, Thompson WH, Notgi A, Harding LK. Radiation doses from nuclear medicine patients to an imaging technologist: relation to ICRP recommendations for pregnant workers. Nucl Med Commun 1992;13:795-8.
11. Williams ED. Imaging and other diagnostic and research in vivo procedures. In: Goldstone Ke, Jackson PC, Myers MJ, Simpson AE, editors. Radiation protection in nuclear medicine and pathology. New York: The Institute of Physical Sciences in Medicine; 1991. p.35-51.
12. Wasserman H, Groenewald W. Air kerma rate constants for radio-nuclides. Eur J Nucl Med 1988;14:569-71.
13. Mountford PJ, O'Dohorty MJ, Forge NI, Jeffries A, Coakley AJ. Radiation dose rates from adult patients undergoing nuclear medicine investigations. Nucl Med Commun 1991;12:767-77.
14. Harding LK, Harding NJ, Warren H, Mills A, Thomson WH. The radiation dose to accompanying nurses, relatives and other patients in a nuclear medicine waiting room. Nucl Med Commun 1990;11:17-22.